These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16819279)
1. Delayed allograft rejection by the suppression of class II transactivator. Kim TW; Choi YM; Seo JN; Kim JH; Suh YH; Chung DH; Jung KC; Oh KI Exp Mol Med; 2006 Jun; 38(3):210-6. PubMed ID: 16819279 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection. Felix NJ; de Serres S; Meyer AA; Ting JP J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017 [TBL] [Abstract][Full Text] [Related]
3. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
4. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites. Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052 [TBL] [Abstract][Full Text] [Related]
5. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565 [TBL] [Abstract][Full Text] [Related]
6. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells. Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519 [TBL] [Abstract][Full Text] [Related]
7. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice. Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097 [TBL] [Abstract][Full Text] [Related]
8. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139 [TBL] [Abstract][Full Text] [Related]
10. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis. Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421 [TBL] [Abstract][Full Text] [Related]
11. Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene. Yang Y; Dai W; Chen Z; Yan Z; Yao Z; Zhang C Biosci Trends; 2013 Feb; 7(1):50-5. PubMed ID: 23524893 [TBL] [Abstract][Full Text] [Related]
12. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins. Broxmeyer HE; Cooper S; Hangoc G; Chang CH Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831 [TBL] [Abstract][Full Text] [Related]
14. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter. Choi YE; Yu HN; Yoon CH; Bae YS Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634 [TBL] [Abstract][Full Text] [Related]
15. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. Shi B; Vinyals A; Alia P; Broceño C; Chen F; Adrover M; Gelpi C; Price JE; Fabra A Int J Biochem Cell Biol; 2006; 38(4):544-62. PubMed ID: 16343978 [TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of class II transactivator-deficient cardiac allografts. June Brickey W; Felix NJ; Griffiths R; Zhang J; Wang B; Piskurich JF; Itoh-Lindstrom Y; Coffman TM; Ting JP Transplantation; 2002 Nov; 74(9):1341-8. PubMed ID: 12451276 [TBL] [Abstract][Full Text] [Related]
17. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420 [TBL] [Abstract][Full Text] [Related]
18. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart. Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978 [TBL] [Abstract][Full Text] [Related]